A PYMNTS Company

US: Teva Pharmaceuticals to increase offer for Mylan to $43 billion

By  |  July 6, 2015

Teva Pharmaceuticals Industries is planning to increase its offer to acquire Mylan to as much as $43 billion, according to report from Bloomberg based on information from people familiar with the situation.

    Get the Full Story

    Complete the form to unlock this article and enjoy unlimited free access to all PYMNTS content — no additional logins required.

    yesSubscribe to our daily newsletter, PYMNTS Today.

    By completing this form, you agree to receive marketing communications from PYMNTS and to the sharing of your information with our sponsor, if applicable, in accordance with our Privacy Policy and Terms and Conditions.

    The people suggested that Teva Pharmaceuticals would announce its sweetened offer as early as this week. It is likely for Teva Pharmaceuticals to raise its acquisition proposal for Mylan between $86 and $88 per share.

    According to the people, Teva Pharmaceuticals intend to formally submit its proposal to Mylan as part of its strategy to prevent it from pursuing its acquisition of Perrigo Company.

    Full content: Bloomberg

    Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.